Skip to main content

Table 1 Baseline characteristics of patients in the erenumab clinical trials [23, 24, 28]

From: Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

CharacteristicEpisodic migraine
(NCT02456740)
STRIVE
Episodic migraine
(NCT02483585)
ARISE
Chronic migraine
(NCT02066415)
PlaceboErenumab
70 mg
Erenumab
140 mg
PlaceboErenumab
70 mg
PlaceboErenumab
70 mg
Erenumab
140 mg
Number of patients319317319291286286191190
Mean age, years (SD)41.3 (11.2)41.1 (11.3)40.4 (11.1)42.2 (11.5)42.3 (11.4)42.1 (11.3)41.4 (11.3)42.9 (11.1)
Sex, n (%)
 Male45 (14.1)48 (15.2)47 (14.7)44 (15.1)41 (14.3)60 (21.0)25 (13.1)30 (15.8)
 Female274 (85.9)269 (84.8)272 (85.3)247 (84.9)245 (85.7)226 (79.0)166 (86.9)160 (84.2)
Race, n (%)
 White276 (86.8)280 (88.6)293 (91.9)259 (89.0)259 (90.6)268 (93.7)176 (92.1)184 (96.8)
 Black24 (7.5)24 (7.6)18 (5.6)27 (9.3)24 (8.4)11 (3.8)10 (5.2)6 (3.2)
 Other18 (5.7)12 (3.8)8 (2.5)5 (1.7)3 (1.0)7 (2.5)5 (2.6)0 (0.0)
MMD8.2 ± 2.58.3 ± 2.58.3 ± 2.58.4 ± 2.68.1 ± 2.718.2 ± 4.717.9 ± 4.417.8 ± 4.7
  1. Abbreviations: ARISE A phase 3, Randomised, double-blind, placebo-controlled Study to Evaluate the efficacy and safety of AMG 334 in migraine prevention, MMD monthly migraine day, SD standard deviation, STRIVE Study to evaluate the efficacy and safety of erenumab in migraine prevention